Figure 7
Figure 7. H2O2 control Bim expression through regulation of Foxo3a levels in T-cell blasts. (A) Day-6 T-cell blasts were cultured in the presence of 30 IU/mL of IL-2 for 24 hours in the absence of any additional treatment (Control) or in the presence of 5 mM GSH, 400 μM BSO, 1 μM DPI, or 1 μg/ml of NOK-1, as indicated. After the treatments, the intracellular levels of H2O2 were determined by DCF-DA staining and flow cytometry, with similar percentages of increase or decrease as shown in Figure 6A (not shown), or extracts were obtained and anti-Foxo3a, anti–phospho-Foxo3a (P-Foxo3a), or anti–β-actin immunoblots performed. Results are representative of experiments performed with T-cell blasts from 4 different healthy donors. (B) Anti-Foxo3a or anti–β-actin immunoblots were performed on extracts from fresh PBMCs (day 0) or from day-6 T-cell blasts (day 6), obtained from healthy donors (Control) or from ALPS-Ia patient 2 (left panels), or from day-6 T cell blasts obtained from healthy donors (Control) or from ALPS-Ic patient 1 (right panels), as indicated. The extracts used correspond to 1 × 106 cells. Results are representative of experiments performed with T-cell blasts from 3 different healthy donors and of 2 different experiments performed with T cells from the ALPS patients. The vertical line in the left subpanel of panel B is due to smear of the sample, revealed in the immunoblot. The samples shown in each immunoblot panel were run in the same gel.

H2O2 control Bim expression through regulation of Foxo3a levels in T-cell blasts. (A) Day-6 T-cell blasts were cultured in the presence of 30 IU/mL of IL-2 for 24 hours in the absence of any additional treatment (Control) or in the presence of 5 mM GSH, 400 μM BSO, 1 μM DPI, or 1 μg/ml of NOK-1, as indicated. After the treatments, the intracellular levels of H2O2 were determined by DCF-DA staining and flow cytometry, with similar percentages of increase or decrease as shown in Figure 6A (not shown), or extracts were obtained and anti-Foxo3a, anti–phospho-Foxo3a (P-Foxo3a), or anti–β-actin immunoblots performed. Results are representative of experiments performed with T-cell blasts from 4 different healthy donors. (B) Anti-Foxo3a or anti–β-actin immunoblots were performed on extracts from fresh PBMCs (day 0) or from day-6 T-cell blasts (day 6), obtained from healthy donors (Control) or from ALPS-Ia patient 2 (left panels), or from day-6 T cell blasts obtained from healthy donors (Control) or from ALPS-Ic patient 1 (right panels), as indicated. The extracts used correspond to 1 × 106 cells. Results are representative of experiments performed with T-cell blasts from 3 different healthy donors and of 2 different experiments performed with T cells from the ALPS patients. The vertical line in the left subpanel of panel B is due to smear of the sample, revealed in the immunoblot. The samples shown in each immunoblot panel were run in the same gel.

Close Modal

or Create an Account

Close Modal
Close Modal